InVentiv bets on PR with Chandler Chicco pickup

Share this article:
Snowballing InVentiv Health signaled interest in the PR sector with its pickup of a big independent PR shop.

The firm last month announced two acquisitions—those of indie healthcare PR shop Chandler Chicco Agency and AWAC, which offers cost containment services to medical payors.

The healthcare marketing and communications company's acquisition of the PR firm, which boasts gross income of $50 million and a staff of 250 spread throughout offices in New York, Los Angeles, Washington, London and Paris, follows its pickup of Chamberlain PR in February.
The addition gives the company a broad-based shop with a substantial corporate practice and international reach to compliment Chamberlain's high-science product PR focus. InVentiv Communications president and CEO R. Blane Walter called Chandler Chicco a good fit in a sector primed for expansion.

“They're kind of the InChord of the PR space,” he said, referring to InVentiv's advertising predecessor company. “The PR environment is growing as people look for more creative ways to reach consumers in a cost-efficient manner.”

Chandler Chicco also deepens InVentiv's relationships with key clients including Allergan, Sanofi-Aventis, Bristol-Myers Squibb and Novartis. Robert Chandler and Gianfranco Chicco will continue to lead the business, reporting to InVentiv Communications president and COO William O'Donnell.

Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.